Prognostic and functional significance of MAP4K5 in pancreatic cancer

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Wang, Oliver H ^a   Azizian, Nancy ^a   Guo, Ming ^a   Capello, Michela ^a   Deng, Defeng ^a   Zang, Fenglin ^a   Fry, Jason ^a   Katz, Matthew H ^a   Fleming, Jason B ^a   Lee, Jeffrey E ^a   Wolff, Robert A ^a   Hanash, Samir ^a   Wang, Huamin ^a   Maitra, Anirban ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 2; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ONCOPROTEIN; OXALIPLATIN; PROTEIN MAP4K5; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CES2 PROTEIN, HUMAN; MAP4K5 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEQUENCE HOMOLOGY; TISSUE MICROARRAY; TUMOR VOLUME; ADENOCARCINOMA; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOBLOTTING; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CADHERINS; CARBOXYLESTERASE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84962132647     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152300     Document Type: Article

References (30)

1. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10):1218-49. PMID: 16702400.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008. PMID: 18287387.
3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21. doi: 10.1158/0008-5472. CAN-14-0155 PMID: 24840647.
4. Neesse A, Gress TM. Emerging role of microRNAs to tackle drug resistance in pancreatic cancer. Gut. 2015. doi: 10.1136/gutjnl-2015-309503 PMID: 26041749.
5. Beuran M, Negoi I, Paun S, Ion AD, Bleotu C, Negoi RI, et al. The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. Pancreatology. 2015;15(3):217-25. doi: 10.1016/j.pan. 2015.02.011 PMID: 25794655.
6. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69(14):5820-8. doi: 10.1158/0008-5472. CAN-08-2819 PMID: 19584296; PubMed Central PMCID: PMC4378690.
7. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415-28. doi: 10.1038/nrc2131 PMID: 17508028.
8. Barriere G, Fici P, Gallerani G, Fabbri F, Rigaud M. Epithelial Mesenchymal Transition: a double-edged sword. ClinTransl Med. 2015;4:14. doi: 10.1186/s40169-015-0055-4 PMID: 25932287; PubMed Central PMCID: PMC4409604.
9. Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGF beta in cancer. FEBS Lett. 2012;586(14):1959-70. doi: 10.1016/j.febslet.2012.02.037 PMID: 22710176.
10. Hu MC, Qiu WR, Wang X, Meyer CF, Tan TH. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev. 1996;10(18):2251-64. PMID: 8824585.
11. Kiefer F, Tibbles LA, Anafi M, Janssen A, Zanke BW, Lassam N, et al. HPK1, a hematopoietic protein kinase activating the SAPK/JNK pathway. Embo J. 1996;15(24):7013-25. PMID: 9003777.
12. Wang H, Chen Y, Lin P, Li L, Zhou G, Liu G, et al. The CUL7/F-box and WD repeat domain containing 8 (CUL7/Fbxw8) ubiquitin ligase promotes degradation of hematopoietic progenitor kinase 1. J Biol Chem. 2014;289(7):4009-17. doi: 10.1074/jbc. M113.520106 PMID: 24362026; PubMed Central PMCID: PMC3924268.
13. Wang H, Song X, Logsdon C, Zhou G, Evans DB, Abbruzzese JL, et al. Proteasome-mediated degradation and functions of hematopoietic progenitor kinase 1 in pancreatic cancer. Cancer Res. 2009;69(3):1063-70. doi: 10.1158/0008-5472. CAN-08-1751 PMID: 19141650; PubMed Central PMCID: PMC4403239.
14. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci USA. 2006;103(10):3775-80. doi: 10.1073/pnas.0600040103 PMID: 16537454; PubMed Central PMCID: PMC1383649.
15. Wright JH, Wang X, Manning G, La Mere BJ, Le P, Zhu S, et al. The STE20 kinase HGKis broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol. 2003;23(6):2068-82. PMID: 12612079; PubMed Central PMCID: PMC149462.
16. Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14(21):7043-9. doi: 10.1158/1078-0432. CCR-08-0381 PMID: 18981001.
17. Wang H, Wang H, Zhang W, Fuller GN. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain pathology (Zurich, Switzerland). 2002;12(1):95-107. PMID: 11770905.
18. Guo R, Overman M, Chatterjee D, Rashid A, Shroff S, Wang H, et al. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014;45(5):1015-23. doi: 10.1016/j.humpath.2013.12.016 PMID: 24746206.
19. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2011;117(4):734-43. doi: 10.1002/cncr.25483 PMID: 20922806; PubMed Central PMCID: PMC4403266.
20. Mizuuchi Y, Aishima S, Ohuchida K, Shindo K, Fujino M, Hattori M, et al. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelialmesenchymal transition. Lab Invest. 2015;95(2):193-206. doi: 10.1038/labinvest.2014.138 PMID: 25418581.
21. Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, et al. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015;107(8). doi: 10.1093/jnci/djv132 PMID: 26025324.
22. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000;157(5):1623-31. doi: 10.1016/S0002-9440 (10) 64800-6 PMID: 11073822; PubMed Central PMCID: PMCPMC1885733.
23. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. NatBiotechnol. 2010;28(5):511-5. doi: 10.1038/nbt.1621 PMID: 20436464; PubMed Central PMCID: PMCPMC3146043.
24. Shi CS, Kehrl JH. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). The Journal of biological chemistry. 2003;278(17):15429-34. doi: 10.1074/jbc. M211796200 PMID: 12591926.
25. Ramjaun AR, Angers A, Legendre-Guillemin V, Tong XK, McPherson PS. Endophilin regulates JNK activation through its interaction with the germinal center kinase-like kinase. The Journal of biological chemistry. 2001;276(31):28913-9. doi: 10.1074/jbc. M103198200 PMID: 11384986.
26. Shi CS, Tuscano J, Kehrl JH. Adaptor proteins CRK and CRKL associate with the serine/threonine protein kinase GCKR promoting GCKR and SAPK activation. Blood. 2000;95(3):776-82. PMID: 10648385.
27. Shi CS, Huang NN, Harrison K, Han SB, Kehrl JH. The mitogen-activated protein kinase kinase kinase kinase GCKR positively regulates canonical and noncanonical Wnt signaling in B lymphocytes. Molecular and cellular biology. 2006;26(17):6511-21. doi: 10.1128/MCB.00209-06 PMID: 16914735; PubMed Central PMCID: PMC1592820.
28. Li Z, Park HR, Shi Z, Li Z, Pham CD, Du Y, et al. Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensormotifs. Oncotarget. 2014;5(10):3197-209. PMID: 24912570; PubMed Central PMCID: PMC4102803.
29. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOXversus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25. doi: 10.1056/NEJMoa1011923 PMID: 21561347.
30. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703. doi: 10.1056/NEJMoa1304369 PMID: 24131140.